Phreesia, Inc. (NYSE:PHR) has received an average recommendation of “Moderate Buy” from the thirteen ratings firms currently covering the company, as reported by Bloomberg.com. Out of the thirteen analysts, two have assigned a hold recommendation while eleven have recommended buying Phreesia’s stock. The consensus target price for the next twelve months, according to brokers who have updated their coverage on the stock in the past year, is $37.15.
In regards to recent news about Phreesia, Senior Vice President Michael J. Davidoff sold 1,075 shares of Phreesia stock on Friday, July 21st. The shares were sold at an average price of $31.75 per share, resulting in a total transaction value of $34,131.25. Following this sale, Davidoff now directly owns 93,576 shares of Phreesia’s stock with a value of approximately $2,971,038. The details of this transaction were disclosed in a legal filing with the SEC and can be accessed through a provided hyperlink. Another transaction involved General Counsel Allison C. Hoffman selling 3,256 shares of Phreesia stock on Wednesday, September 13th at an average price of $20.34 per share. This resulted in a total value of $66,227.04 and left Hoffman with 118,532 shares valued at approximately $2,410,-
940.88.
According to SEC filings and reports available on their website, company insiders have collectively sold 21,765 shares worth $454,810 over the last 90 days. This represents about
5.80% ownership stake being transferred from insiders.
Phreesia released its earnings results on Wednesday September 6th which revealed that the company reported earnings per share (EPS) of ($0.68), beating analysts’ expectations by $0.03 per share with revenue totaling $85.80 million for the quarter. Analysts had projected revenue to be around $85.26 million. Despite a negative net margin of 47.75% and a negative return on equity of 54.52%, Phreesia’s revenue for the quarter increased by 26.4% compared to the same quarter last year. In the previous year, the company posted an EPS of ($0.89). Equities analysts expect that Phreesia will post -2.64 EPS in the current year.
In conclusion, Phreesia, Inc., a renowned healthcare technology company, has garnered positive recommendations from analysts and seen substantial insider trading activity in recent months. With its better-than-expected earnings report, despite negative margins and return on equity, there is cautious optimism surrounding Phreesia’s future performance in the market.
[bs_slider_forecast ticker=”MFC”]
Mixed Ratings and Diverse Evaluations: Analyzing Phreesia’s Stock Performance
Phreesia, a leading healthcare software company, has recently received mixed ratings from equities research analysts. Needham & Company LLC has reiterated its “buy” rating on Phreesia stock and set a price target of $40.00. This positive recommendation indicates the analysts’ belief in the company’s growth prospects.
However, there are contrasting opinions as well. Raymond James has lowered its price objective for Phreesia shares from $40.00 to $30.00, but still maintains an “outperform” rating for the company. Similarly, Stephens has given an “overweight” rating on the stock with a price target of $37.00.
Citigroup has also decreased its price target on Phreesia from $40.00 to $37.00 while retaining a “buy” rating on the stock. Royal Bank of Canada, however, has reduced its target price from $33.00 to $29.00 and assigned a “sector perform” rating for Phreesia.
These diverse evaluations showcase the perplexing situation surrounding Phreesia’s stock performance in recent times.
Moving on to institutional investors, several significant players have made changes to their positions in Phreesia lately. Captrust Financial Advisors raised its stake in the company by 154.6% during the second quarter, indicating growing confidence in Phreesia’s potential for success.
Acadian Asset Management LLC also bought a new position in Phreesia earlier this year, signaling trust in the company’s long-term prospects. Additionally, State of Wyoming increased its holdings by 34.6% during the second quarter and Tower Research Capital LLC TRC saw an 85.4% growth in their ownership during the third quarter.
Bessemer Group Inc., another notable investor, acquired a new stake valued at approximately $127,000 earlier this year.
It is worth noting that hedge funds and other institutional investors now own around 94.37% of Phreesia’s stock, which indicates the high level of interest in the company within the investment community.
In terms of financials, Phreesia had an opening price of $18.63 on Friday. The company’s 50-day moving average stands at $25.90, while its 200-day moving average is $29.60 per share. This indicates some fluctuation in the stock price during recent periods.
Furthermore, Phreesia recorded a twelve-month low of $17.44 and a high of $40.00, illustrating the extreme volatility experienced by investors in this period.
With a market capitalization of $1.03 billion and a price-to-earnings ratio of -6.51, Phreesia faces complex challenges as it operates within the healthcare software industry, which requires constant adaptation to regulatory changes and technological advancements.
Considering these various factors, investors and analysts alike find themselves perplexed when evaluating Phreesia’s future performance on the stock market.
Disclaimer: This article should not be considered as financial advice or a recommendation to buy or sell any securities mentioned above. The sole purpose is to provide information for educational purposes only. Seek professional assistance from a certified financial advisor before making any investment decisions based on this article’s content.
